ARCA biopharma

ARCA biopharma, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of targeted therapies for cardiovascular diseases. The firm focuses on the cardiovascular pathophysiology, molecular genetics, and clinical development. Its product candidate, Gencaro is a pharmacologic beta-blocker and mild vasodilator, which is developed for the treatment of chronic heart failure and other indications. The company was founded by Michael R. Bristow and Christopher David Ozeroff in 1992 and is headquartered in Westminster, CO.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Oruka Therapeutics, Inc. is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.

The combined company will operate as “Oruka Therapeutics, Inc.” with its common stock traded on Nasdaq under trading symbol “ORKA” effective Tuesday, September 3, 2024 The combined company will operate as “Oruka Therapeutics, Inc.” with its common stock traded on Nasdaq under trading symbol “ORKA” effective Tuesday, September 3, 2024

ARCA biopharma Announces Completion of Merger with Oruka Therapeutics and Implementation of Reverse Stock Split

WESTMINSTER, Colo., Aug. 26, 2024 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (NASDAQ: ABIO) (“ARCA”) today announced an update to the previously announced final amount of the special cash dividend (the “Special Dividend”), which will now equal $1.613 per share of ARCA's common stock, payable on August 28, 2024, to ARCA's stockholders of record as of August 26, 2024. The Special Dividend was declared by ARCA's Board of Directors on August 16, 2024, in connection with the previously announced merger (the “Merger”) with Oruka Therapeutics, Inc. (“Oruka”), pursuant to the Agreement and Plan of Merger and Reorganization, dated April 3, 2024 (the “Merger Agreement”). The exact amount of the Special Dividend was calculated in accordance with the Merger Agreement and based on ARCA's reasonable, good faith approximation of the amount by which ARCA's net cash, as determined prior to the closing of the Merger, will exceed $5,000,000.

ARCA biopharma Provides Update Regarding Special Dividend Amount in Connection with the Proposed Merger with Oruka Therapeutics

WESTMINSTER, Colo., Aug. 23, 2024 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (NASDAQ: ABIO) (“ARCA”) today announced that its Board of Directors (the “Board”) has approved a reverse stock split of ARCA's common stock at a ratio of 1-for-12. ARCA's common stock is expected to begin trading on a post-reverse stock split basis on The Nasdaq Global Market on September 3, 2024, under the new name Oruka Therapeutics, Inc. and under the new symbol “ORKA” following the anticipated closing of the merger with Oruka Therapeutics, Inc. (the “Merger”), with a new CUSIP number 687604108 and ISIN number US6876041087.

ARCA biopharma Announces 1-for-12 Reverse Stock Split in Connection with the Proposed Merger with Oruka Therapeutics

Special dividend estimated to be $1.59 per share Payment of special dividend conditioned upon ARCA stockholder approval of the Proposed Merger with Oruka WESTMINSTER, Colo., Aug. 16, 2024 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (NASDAQ: ABIO) (“ARCA”) today announced that its Board of Directors has declared a special cash dividend (the “Special Dividend”) in connection with the previously announced merger (the “Merger”) with Oruka Therapeutics, Inc. (“Oruka”) pursuant to the Agreement and Plan of Merger and Reorganization, dated April 3, 2024 (the “Merger Agreement”).

ARCA biopharma Declares Special Dividend in Connection with the Proposed Merger with Oruka Therapeutics

WESTMINSTER, Colo., Aug. 01, 2024 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), (the “Company”) a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today reported second quarter 2024 financial results and provided a corporate update.

ARCA biopharma Announces Second Quarter 2024 Financial Results and Provides Corporate Update

MILWAUKEE , June 4, 2024 /PRNewswire/ -- Ademi LLP is investigating ARCA (NASDAQ: ABIO) for possible breaches of fiduciary duty and other violations of law in its transaction with Oruka. Click here to learn how to join the https://www.ademilaw.com/case/arca-biopharma-inc or call Guri Ademi toll-free at 866-264-3995.

Shareholder Alert: Ademi LLP investigates Disclosure Issues involving ARCA biopharma, Inc.'s Transaction with Oruka

Rent the Runway

SilverSun Technologies

Yesterday, the forgotten meme stocks of 2021 started picking up serious momentum. But unlike 2021, it didn't take much to see the reason behind GameStop's (NYSE: GME ) sudden surge.

3 Short-Squeeze Stocks Ready to Soar on Roaring Kitty Rally

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of ARCA biopharma, Inc. (the “Company”) (NasdaqCM: ABIO) and Oruka Therapeutics. Upon closing of the proposed transaction, ARCA shareholders are expected to own approximately 2.38% of the combined company. KSF is seeking to determine whether the merger and the process that led to it are adequate, and whether th.

ARCA BIOPHARMA INVESTOR ALERT By the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of ARCA biopharma, Inc. - ABIO

ARCA biopharma and Oruka Therapeutics announce Merger Agreement ARCA biopharma appoints Thomas Keuer as President WESTMINSTER, Colo., April 25, 2024 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), (the “Company”) a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today reported first quarter 2024 financial results and provided a corporate update.

ARCA biopharma Announces First Quarter 2024 Financial Results and Provides Corporate Update

NEW YORK , April 9, 2024 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and is investigating ARCA Biopharma, Inc. (Nasdaq: ABIO), relating to its proposed merger to Oruka Therapeutics.

SHAREHOLDER INVESTIGATION: The M&A Class Action Firm Announces an Investigation of ARCA Biopharma, Inc. - ABIO

ARCA BIOPHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of ARCA biopharma, Inc. - ABIO

Clinical-stage biopharmaceutical firm ARCA Biopharma (NASDAQ: ABIO ) — which develops and commercializes cardiovascular disease therapies — saw its shares skyrocket during the midweek session. Earlier this morning, management announced a merger with Oruka Therapeutics, which ultimately aims to address chronic skin diseases.

Why Is ARCA Biopharma (ABIO) Stock Up 85% Today?

MILWAUKEE , April 3, 2024 /PRNewswire/ -- Ademi LLP is investigating ARCA (NASDAQ: ABIO) for possible breaches of fiduciary duty and other violations of law in its transaction with Oruka. Click here to learn how to join the https://www.ademilaw.com/case/arca-biopharma-inc or call Guri Ademi toll-free at 866-264-3995.

Shareholder Alert: Ademi LLP investigates whether ARCA biopharma, Inc. has obtained a Fair Price in its transaction with Oruka

Arca Biopharma Inc (NASDAQ: ABIO) more than doubled on Wednesday after announcing a merger agreement with Oruka Therapeutics. Oruka CEO comments on Arca Biopharma stock deal The combined company following completion of the all-stock transaction will operate as Oruka Therapeutics and trade under “ORKA” on Nasdaq.

Arca Biopharma stock ($ABIO) soars on merger news

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of ARCA biopharma, Inc. (NASDAQ: ABIO) and Oruka Therapeutics is fair to ARCA shareholders. Upon closing of the proposed transaction, ARCA shareholders are expected to own approximately 2.38% of the combined company. Halper Sadeh encourages ARCA shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sa.

ABIO Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of ARCA Biopharma, Inc. Is Fair to Shareholders

Merger to create a company focused on advancing Oruka's portfolio of novel biologics that aim to redefine the standard of care for patients with chronic skin diseases

ARCA biopharma and Oruka Therapeutics Announce Merger Agreement

Company is currently engaged in a strategic review process, evaluating additional development of its assets, collaborations and other strategic options WESTMINSTER, Colo., Feb. 01, 2024 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today reported 2023 financial results and provided a corporate update.

ARCA biopharma Announces 2023 Financial Results

Company is currently engaged in a strategic review process, evaluating additional development of its assets, collaborations and other strategic options WESTMINSTER, Colo., Oct. 18, 2023 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today reported third quarter 2023 financial results and provided a corporate update.

ARCA biopharma Announces Third Quarter 2023 Financial Results

WESTMINSTER, Colo., July 21, 2023 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today reported second quarter 2023 financial results and provided a corporate update.

ARCA biopharma Announces Second Quarter 2023 Financial Results

Company is currently engaged in a strategic review process, evaluating additional development of its assets, collaborations and other strategic options Company is currently engaged in a strategic review process, evaluating additional development of its assets, collaborations and other strategic options

ARCA biopharma Announces First Quarter 2023 Financial Results

ARCA biopharma Announces 2022 Financial Results and Provides Corporate Update

WESTMINSTER, Colo., Dec. 19, 2022 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO) today announced that James Flynn has joined its Board of Directors.

James Flynn Joins ARCA biopharma Board of Directors

ARCA biopharma Announces Third Quarter 2022 Financial Results

WESTMINSTER, Colo., Aug. 02, 2022 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today reported second quarter 2022 financial results and provided a corporate update.

ARCA biopharma Announces Second Quarter 2022 Financial Results

WESTMINSTER, Colo., June 21, 2022 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO) today announced that Jacob Ma-Weaver has joined its Board of Directors.

News for ARCA biopharma Stock (ABIO)